Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments

被引：9
作者：
Arav-Boger, Ravit [1 ]
机构：
[1] Johns Hopkins Univ Hosp, Dept Pediat, Div Infect Dis, Baltimore, MD 21287 USA
来源：
VIRUS GENES | 2009年 / 38卷 / 02期
关键词：
Kaposi sarcoma herpes virus; Primary effusion lymphoma; Highly active antiretroviral therapy; Antivirals; Ganciclovir; Chemotherpy; Tyrosine kinase inhibitors; Angiogenesis inhibitors; MTOR; Rapamycin; PRIMARY EFFUSION LYMPHOMA; PEGYLATED-LIPOSOMAL DOXORUBICIN; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MULTICENTRIC CASTLEMAN-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; AIDS MALIGNANCY CONSORTIUM; PROTEIN-COUPLED RECEPTOR; TRANS-RETINOIC ACID; PHASE-II TRIAL; IN-VIVO;
D O I：
10.1007/s11262-008-0325-y
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.
引用
收藏
页码：195 / 203
页数：9
相关论文
共 72 条
[1]   PS-341 or a combination of arsenic trioxide and interferon-α inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells [J].
Abou-Merhi, R. ;
Khoriaty, R. ;
Arnoult, D. ;
El Hajj, H. ;
Dbouk, H. ;
Munier, S. ;
El-Sabban, M. E. ;
Hermine, O. ;
Gessain, A. ;
de The, H. ;
Mahieux, R. ;
Bazarbachi, A. .
LEUKEMIA, 2007, 21 (08) :1792-1801
[2]   Kaposi's sarcoma [J].
Antman, K ;
Chang, Y .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) :1027-1038
[3]   G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator [J].
Bais, C ;
Santomasso, B ;
Coso, O ;
Arvanitakis, L ;
Raaka, EG ;
Gutkind, JS ;
Asch, AS ;
Cesarman, E ;
Gerhengorn, MC ;
Mesri, EA .
NATURE, 1998, 391 (6662) :86-89
[4]   Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells [J].
Blankaert, D ;
Simonart, T ;
Van Vooren, JP ;
Parent, D ;
Liesnard, C ;
Farber, CM ;
Marique, T ;
Werenne, J .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 (03) :203-209
[5]  
Brenner B, 1999, INT J ONCOL, V14, P1097
[6]   Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma [J].
Bundow, D ;
Aboulafia, DM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01) :81-84
[7]   Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions [J].
Caccialanza, M. ;
Marca, S. ;
Piccinno, R. ;
Eulisse, G. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (03) :297-302
[8]  
Casper C, 2007, CURR TOP MICROBIOL, V312, P289
[9]   Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment [J].
Casper, C ;
Nichols, WG ;
Huang, ML ;
Corey, L ;
Wald, A .
BLOOD, 2004, 103 (05) :1632-1634
[10]   Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial [J].
Casper, Corey ;
Krantz, Elizabeth M. ;
Corey, Lawrence ;
Kuntz, Steven R. ;
Wang, Jie ;
Selke, Stacy ;
Hamilton, Shannon ;
Huang, Meei-Li ;
Wald, Anna .
JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (01) :23-30
12345678